HCPCS code P9053 – Irradiated, CMV-negative platelet billing

Key takeaways

HCPCS Code P9053 covers one apheresis platelet unit that is leukoreduced, CMV-negative and irradiated, billed per unit transfused.

P9055 is the same product without irradiation, P9037 is irradiated and leukoreduced without CMV-negative status, and P9052 covers HLA-matched platelets.

Irradiation prevents transfusion-associated graft-versus-host disease, so the order and record should name the patient’s irradiation indication.

Most hospitals report P9053 under revenue code 0390 because the blood supplier charges only for processing, and never add CPT 86945 for the irradiation.

Medicare pays P9053 separately under OPPS with status indicator R, so check the current Addendum B for the national rate.

HCPCS Code P9053: definition and official descriptor

HCPCS Code P9053 is a Level II code that the Centers for Medicare and Medicaid Services (CMS) maintains in its Healthcare Common Procedure Coding System. The official long descriptor reads: Platelets, pheresis, leukocytes reduced, CMV-negative, irradiated, each unit.

Every term in that descriptor is a coding condition. Pheresis means a single-donor collection. Leukocytes reduced means the white cells were filtered out. CMV-negative means the donor tested seronegative for cytomegalovirus, and irradiated means the unit was treated to inactivate donor lymphocytes.

P9053 requires all three attributes at once. A unit missing any one of them belongs to a different code, which the comparison section below maps out. Code descriptors here follow the AABB billing guide for blood products and the CMS HCPCS file.

Clinical context: who needs irradiated, CMV-negative platelets

Irradiation exists to prevent transfusion-associated graft-versus-host disease (TA-GvHD). Donor T-lymphocytes in an unirradiated unit can engraft in a recipient who cannot reject them. The British Society for Haematology (BSH) describes TA-GvHD as rare but usually fatal.

The BSH 2020 guidelines on the use of irradiated blood components list the patient groups that need irradiated cellular components. The main indications are:

• Stem cell transplant: allogeneic transplant recipients, and autologous recipients from stem cell collection until recovery.
• Severe T-cell immunodeficiency: congenital conditions such as severe combined immunodeficiency (SCID), and DiGeorge syndrome with T-cell deficiency.
• Purine analogues and bendamustine: patients treated with fludarabine, cladribine, pentostatin or bendamustine.
• T-cell depleting antibodies: alemtuzumab, and antithymocyte globulin (ATG) given for aplastic anemia.
• Hodgkin lymphoma: patients at any stage of the disease.
• Fetal and neonatal transfusion: intrauterine transfusion, and neonatal exchange transfusion after an intrauterine transfusion.
• Related or HLA-matched donors: directed donations from blood relatives and HLA-matched components, whatever the recipient’s immune status.

CMV-negative status addresses a separate risk: cytomegalovirus transmission to a seronegative, immunocompromised recipient. Many blood services treat leukoreduction as CMV-safe, so the CMV-negative specification follows local transfusion policy. When the order asks for it and the label confirms it, the unit qualifies for P9053.

What P9053 covers and what it excludes

P9053 pays for the platelet product itself. The transfusion procedure and some related laboratory services carry their own codes.

Irradiation is already built into P9053. The AABB billing guide states that billing irradiation CPT code 86945 alongside an irradiated P-code is never appropriate. If an irradiated unit is prepared but not transfused, the hospital may bill 86945 for the irradiation, but not the P-code.

P9053 vs P9055, P9037 and other platelet codes

The apheresis platelet codes differ by one or two processing attributes. Picking the right one means reading the unit label against each descriptor.

The one-attribute pair is P9053 and P9055. Both describe leukoreduced, CMV-negative apheresis platelets, and only irradiation separates them. P9037 is the other close neighbor. It is irradiated and leukoreduced, but its descriptor carries no CMV-negative specification.

The order logic runs in a fixed sequence. Irradiated, leukoreduced, CMV-negative apheresis platelets are P9053. Leukoreduced, CMV-negative apheresis platelets without irradiation are P9055. HLA-matched leukoreduced apheresis platelets are P9052. P9035 covers leukoreduced apheresis platelets with neither attribute specified. Apheresis platelets with no leukoreduction, irradiation or CMV-negative label are HCPCS P9034. P9032 describes irradiated platelets without the apheresis or leukoreduction terms.

For leukoreduced apheresis units that are not HLA-matched, two label checks settle the code, as the matrix below shows.

How to bill HCPCS Code P9053: step-by-step

Accurate P9053 billing matches the blood bank issue record to the claim line, unit by unit. The steps below take a unit from the order to the submitted claim.

1. Check the order. Confirm it asks for irradiated, CMV-negative, leukoreduced apheresis platelets and states the indication.
2. Check the unit label and issue record. Both must show all three attributes, plus the unit number and issue time.
3. Count the units transfused. Report one unit of P9053 for each apheresis unit transfused, matched to the issue log.
4. Add the diagnosis codes. Report the condition that drove the platelet transfusion and the condition that called for irradiation.
5. Pick the revenue code. Use 0390 when the supplier charged only for processing, or 0384 with modifier BL when the hospital bought the blood itself.
6. Report the transfusion separately. Bill CPT 36430 once per session under revenue code 0391, and never add 86945 to the same unit.

Revenue codes and claim form requirements

Revenue code choice depends on what the hospital paid for. According to the AABB billing guide, most hospitals get blood from community blood centers that charge only for processing and storage. Those hospitals report the P9053 line under revenue code 0390.

Revenue code series 038X, modifier BL and blood-related value codes apply only when the hospital bills for the blood itself. A processing-only claim uses none of them. Hospital outpatient claims go on the UB-04, with P9053 in form locator 44.

Medicare does not require an NDC on a P-coded blood component line. Blood components carry ISBT 128 product codes on their labels rather than NDCs. Some state Medicaid programs and commercial payers set their own drug-reporting rules, so check each payer’s policy.

Modifiers used with P9053

Most processing-only P9053 claims need no modifier. Modifier BL (special acquisition of blood and blood products) applies only when the hospital bills the cost of the blood under revenue code 038X. The JW and JZ discarded-drug modifiers apply to single-dose drug containers, and P-series blood codes are outside that policy.

NCCI edits also govern which blood codes can share a claim. Per the AABB guide, certain non-irradiated platelet P-codes are not paid when billed with an irradiated P-code on the same outpatient claim and date. Review the current NCCI edits before you report P9053 next to another platelet code.

Medicare reimbursement for P9053

Medicare pays hospital outpatient claims for P9053 under the Outpatient Prospective Payment System (OPPS). Blood product P-codes carry status indicator R and sit in their own Ambulatory Payment Classifications (APCs). The national rate changes with each annual OPPS final rule and quarterly update, so check the CMS OPPS Addendum B for the date of service.

• Outpatient (Part B): the P9053 line earns its own APC payment, adjusted by the hospital’s wage index.
• Transfusion procedure: CPT 36430 earns a separate APC payment, and OPPS edits expect a blood product P-code on the same claim.
• Inpatient (Part A): blood products fall within the MS-DRG payment and are not paid separately through P9053.
• Blood deductible: the Medicare blood deductible covers whole blood and red cell units, so it does not apply to platelets.
• Other payers: Medicare Advantage and commercial contracts set their own blood product rates, so check each contract.

Track P9053 payments against what your blood supplier charges each year. Effective revenue cycle management for blood products means spotting a rate change before it erodes the margin on every unit.

Documentation requirements for P9053 claims

A P9053 claim stands on a complete chain from order to transfusion. Payers check both the product attributes and the reason for them. Building that chain before submission is core to medical billing compliance.

• Physician order: names irradiated, CMV-negative, leukoreduced apheresis platelets, and is signed and dated before administration.
• Indication for irradiation: the record states why the patient needs irradiated components, such as a stem cell transplant or purine analogue therapy.
• Unit label: the label confirms leukoreduction, CMV-negative status and irradiation. Keep a copy or scan in the transfusion record.
• Blood bank issue record: shows the product code, unit number, issue date and time, and patient identifier.
• Transfusion administration note: records start and stop times, vital signs and any reaction for each unit.
• Disposition record: confirms each billed unit was transfused, since hospitals cannot bill for unused blood.

ICD-10 diagnosis codes that document irradiated-product need

No Medicare national or local coverage determination sets a diagnosis list for P9053. The codes below are diagnoses that commonly document the need for irradiated components, based on the BSH 2020 indication list. They are examples, not a payer-accepted list.

Use the most specific code the record supports, rather than an unspecified variant. Confirm current code status in the CDC ICD-10-CM browser before you submit.

Common denial reasons for P9053 and how to avoid them

Most P9053 problems start when the order, the unit label and the claim line disagree. A front-end check catches them before submission, which is the core of denial management in healthcare.

Read the CARC and RARC on the remittance before you rework the claim. CARC 50 signals a medical necessity dispute, while CARC 16 points to missing information or a billing error. The denial codes in medical billing guide maps each code to its fix.

How Pabau supports accurate P9053 billing

A P9053 claim depends on records that often live in separate places. The order sits in the chart, the unit label sits with the blood bank, and the charge sits in billing. A mismatch between them stays hidden until the remittance arrives.

Pabau, the practice management and billing platform we build, keeps the order, scanned unit labels and the invoice on one patient record. For US payers, Pabau’s claims management software pre-fills claims from data already on the record and submits them through Claim.MD. Your team then tracks each claim’s status and denial reason in one place.

When a payer asks for records on a P9053 line, staff pull the order and label from the same record as the invoice. That turns an audit request into a document pull rather than a search across systems.

Keep every blood product claim traceable

Pabau keeps the order, unit records and invoice on one patient record. Your team matches each P9053 charge to its records and tracks every denial reason in one place.

Book a demo

Conclusion

P9053 is the code for one specific product: an apheresis platelet unit that is leukoreduced, CMV-negative and irradiated. Treat the unit label as the source of truth, and code from all three attributes. Drop irradiation and the line becomes P9055, while dropping CMV-negative status makes it P9037.

Two checks carry most of the risk. Confirm the order states the irradiation indication, and keep CPT 86945 off any unit already billed as P9053. Running both on every platelet line keeps audits short.

Book a demo to see how Pabau keeps orders, unit records and invoices together for every transfusion claim.

Continue your research

Need a full denial management framework? Denial management in healthcare covers root-cause analysis, appeal workflows, and denial prevention strategies for outpatient billing teams.

Unfamiliar with clean claim requirements? What makes a clean claim explains the data elements payers check on submission and how to prevent common edit failures.

Looking to understand the broader billing picture? What is medical billing covers the end-to-end revenue cycle from charge capture through payment posting.

Frequently asked questions